[go: up one dir, main page]

WO1999048868A3 - Heterocyclic classes of compounds for the modulating tyrosine protein kinase - Google Patents

Heterocyclic classes of compounds for the modulating tyrosine protein kinase Download PDF

Info

Publication number
WO1999048868A3
WO1999048868A3 PCT/US1999/006468 US9906468W WO9948868A3 WO 1999048868 A3 WO1999048868 A3 WO 1999048868A3 US 9906468 W US9906468 W US 9906468W WO 9948868 A3 WO9948868 A3 WO 9948868A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
protein kinase
tyrosine protein
modulating
modulating tyrosine
Prior art date
Application number
PCT/US1999/006468
Other languages
French (fr)
Other versions
WO1999048868A9 (en
WO1999048868A2 (en
Inventor
Annie Fong
Alison Hannah
David G Harris
Peter Hirth
Steven R Hubbard
Peter Langecker
Congxin Liang
Gerald Mcmahon
Moosa Mohammadi
Joseph Schlessinger
Laura K Shawver
Li Sun
Peng C Tang
Axel Ullrich
Original Assignee
Sugen Inc
Univ New York
Max Planck Inst Fur Biochemie
Annie Fong
Alison Hannah
David G Harris
Peter Hirth
Steven R Hubbard
Peter Langecker
Congxin Liang
Gerald Mcmahon
Moosa Mohammadi
Joseph Schlessinger
Laura K Shawver
Li Sun
Peng C Tang
Axel Ullrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Univ New York, Max Planck Inst Fur Biochemie, Annie Fong, Alison Hannah, David G Harris, Peter Hirth, Steven R Hubbard, Peter Langecker, Congxin Liang, Gerald Mcmahon, Moosa Mohammadi, Joseph Schlessinger, Laura K Shawver, Li Sun, Peng C Tang, Axel Ullrich filed Critical Sugen Inc
Priority to AU33635/99A priority Critical patent/AU3363599A/en
Priority to JP2000537851A priority patent/JP2002507598A/en
Priority to CA002325935A priority patent/CA2325935A1/en
Priority to EP99915018A priority patent/EP1066257A2/en
Publication of WO1999048868A2 publication Critical patent/WO1999048868A2/en
Publication of WO1999048868A3 publication Critical patent/WO1999048868A3/en
Publication of WO1999048868A9 publication Critical patent/WO1999048868A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to certain indolinone-based and pyrazolylamide-based compounds, their method of synthesis, and combinatorial libraries consisting of the compounds. The invention also relates to methods of modulating the function of protein kinases using these compounds and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.
PCT/US1999/006468 1998-03-26 1999-03-26 Heterocyclic classes of compounds for the modulating tyrosine protein kinase WO1999048868A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU33635/99A AU3363599A (en) 1998-03-26 1999-03-26 Heterocyclic families of compounds for the modulation of tyrosine protein kinase
JP2000537851A JP2002507598A (en) 1998-03-26 1999-03-26 A family of heterocyclic compounds for regulating tyrosine protein kinase
CA002325935A CA2325935A1 (en) 1998-03-26 1999-03-26 Heterocyclic families of compounds for the modulation of tyrosine protein kinase
EP99915018A EP1066257A2 (en) 1998-03-26 1999-03-26 Heterocylic classes of compounds for the modulating tyrosine protein kinase

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US7971398P 1998-03-26 1998-03-26
US8042298P 1998-04-02 1998-04-02
US8179298P 1998-04-15 1998-04-15
US8205698P 1998-04-16 1998-04-16
US8939798P 1998-06-15 1998-06-15
US8952198P 1998-06-16 1998-06-16
US9878398P 1998-09-01 1998-09-01
US60/082,056 1998-09-01
US60/089,397 1998-09-01
US60/080,422 1998-09-01
US60/079,713 1998-09-01
US60/081,792 1998-09-01
US60/089,521 1998-09-01
US60/098,783 1998-09-01

Publications (3)

Publication Number Publication Date
WO1999048868A2 WO1999048868A2 (en) 1999-09-30
WO1999048868A3 true WO1999048868A3 (en) 2000-02-24
WO1999048868A9 WO1999048868A9 (en) 2000-04-20

Family

ID=27568389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006468 WO1999048868A2 (en) 1998-03-26 1999-03-26 Heterocyclic classes of compounds for the modulating tyrosine protein kinase

Country Status (5)

Country Link
EP (1) EP1066257A2 (en)
JP (1) JP2002507598A (en)
AU (1) AU3363599A (en)
CA (1) CA2325935A1 (en)
WO (1) WO1999048868A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214700B2 (en) 2000-05-02 2007-05-08 Sugen Inc. (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EA005032B1 (en) 1998-05-29 2004-10-28 Сьюджен, Инк. Pyrrole substituted 2-indolinone (variants), pharmaceutical composition (variants), method for modulation of catalytic activity method for treating and preventing a protein kinase related disorders in an organism
TR200101860T2 (en) 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxidols as cyclin-dependent kinase inhibitors
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
ATE494388T1 (en) 1999-01-13 2011-01-15 Univ New York State Res Found NEW METHOD FOR CREATING PROTEIN KINASE INHIBITORS
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
EP1255536B1 (en) * 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
EP1259234B9 (en) * 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
JP3663382B2 (en) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド Pyrrole-substituted 2-indolinone protein kinase inhibitor
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
WO2002094809A1 (en) * 2001-05-24 2002-11-28 Yamanouchi Pharmaceutical Co., Ltd. 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
WO2003070725A2 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
WO2004043389A2 (en) 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
WO2004048366A1 (en) * 2002-11-22 2004-06-10 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
GT200500321A (en) * 2004-11-09 2006-09-04 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE.
MX2007014782A (en) 2005-05-23 2008-02-19 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts.
RU2430913C2 (en) 2006-01-06 2011-10-10 Сепракор Инк. Cycloalkylamines as monoamine reuptake inhibitors
CN104276955A (en) 2006-01-06 2015-01-14 赛诺维信制药公司 Tetralone-based monoamine reuptake inhibitors
PT2816024T (en) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Chiral amines
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
JP4937881B2 (en) * 2006-11-01 2012-05-23 財団法人工業技術研究院 Azulene compounds
WO2008089453A2 (en) 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008138184A1 (en) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases
NZ580429A (en) 2007-05-31 2012-04-27 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
PL2197280T3 (en) 2007-08-27 2013-11-29 Basf Se Pyrazole compounds for controlling invertebrate pests
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
ES2710701T3 (en) 2008-09-24 2019-04-26 Basf Se Pyrazole compounds for the control of invertebrate pests
PL2342196T3 (en) 2008-09-24 2015-12-31 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2451808B1 (en) 2009-07-06 2014-03-26 Basf Se Pyridazine compounds for controlling invertebrate pests
WO2011003796A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
JP2013500246A (en) 2009-07-24 2013-01-07 ビーエーエスエフ ソシエタス・ヨーロピア Pyridine derivative compounds for invertebrate pest control
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013055A2 (en) * 1990-02-28 1991-09-05 Farmitalia Carlo Erba S.R.L. New aryl- and heteroarylethenylene derivatives and process for their preparation
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
WO1994014808A1 (en) * 1992-12-23 1994-07-07 Farmitalia Carlo Erba Srl Vinylene-azaindole derivatives and process for their preparation
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1996000226A1 (en) * 1994-06-24 1996-01-04 Pharmacia S.P.A. Substituted azaindolylidene compounds and process for their preparation
WO1996016964A1 (en) * 1994-11-28 1996-06-06 Pharmacia & Upjohn S.P.A Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998045708A1 (en) * 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998056376A1 (en) * 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013055A2 (en) * 1990-02-28 1991-09-05 Farmitalia Carlo Erba S.R.L. New aryl- and heteroarylethenylene derivatives and process for their preparation
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
WO1994014808A1 (en) * 1992-12-23 1994-07-07 Farmitalia Carlo Erba Srl Vinylene-azaindole derivatives and process for their preparation
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1996000226A1 (en) * 1994-06-24 1996-01-04 Pharmacia S.P.A. Substituted azaindolylidene compounds and process for their preparation
WO1996016964A1 (en) * 1994-11-28 1996-06-06 Pharmacia & Upjohn S.P.A Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998045708A1 (en) * 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998056376A1 (en) * 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GAZIT,A. ET AL.: "Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenmalonitirle Tyrphostins as Poitent Inhibitors of EGRF Receptor and ErbB2/neu Tyrosine Kinases", J.MED.CHEM., vol. 34, no. 6, June 1991 (1991-06-01), WASHINGTON, pages 1896 - 1907, XP000472938 *
LEVITZKI A ET AL: "TYROSINE KINASE INHIBITION: AN APPROACH TO DRUG DEVELOPMENT", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 267, March 1995 (1995-03-01), pages 1782-1788, XP002048355, ISSN: 0036-8075 *
MOHAMMADI M ET AL: "STRUCTURES OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR IN COMPLEX WITH INHIBITORS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 276, no. 5314, pages 955-960, XP002065235, ISSN: 0036-8075 *
SPADA A P ET AL: "SMALL MOLECULE INHIBITORS OF TYROSINE KINASE ACTIVITY", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 5, no. 8, 1 January 1995 (1995-01-01), pages 805 - 817, XP000567587, ISSN: 1354-3776 *
SUN,LO. ET AL.: "Synthesis and Biological Evaluation of 3-Substituted Indolin-2-ones : A novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particualr Receptor Tyrosine Kinases", J.MED.CHEM., vol. 41, no. 14, 2 July 1998 (1998-07-02), WASHINGTON, pages 2588 - 2603, XP002122185 *
TRAXLER,P.M.: "Protein tyrosine kinase inhibitors in cancer treatment", EXP.OPIN.THER.PATENTS, vol. 7, no. 6, 1997, LONDON, pages 571 - 588, XP002122590 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214700B2 (en) 2000-05-02 2007-05-08 Sugen Inc. (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
EP1066257A2 (en) 2001-01-10
WO1999048868A9 (en) 2000-04-20
WO1999048868A2 (en) 1999-09-30
AU3363599A (en) 1999-10-18
CA2325935A1 (en) 1999-09-30
JP2002507598A (en) 2002-03-12

Similar Documents

Publication Publication Date Title
WO1999048868A3 (en) Heterocyclic classes of compounds for the modulating tyrosine protein kinase
WO2001064681A3 (en) 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
AU7289696A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ATE322491T1 (en) BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
ATE231148T1 (en) BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
GR20010300010T1 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
NO960079L (en) Oligonucleotide modulation of protein kinase C
AU7585598A (en) Raf kinase inhibitors
FI20040649A7 (en) Bicyclic compounds capable of inhibiting epidermal growth factor receptor family tyrosine kinases
CY2014034I1 (en) SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS
IL142121A0 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP0831831A4 (en) Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties
FI972492L (en) Imidazole derivatives as inhibitors of protein kinases, especially EGF-R tyrosine kinase
WO2002048336A3 (en) Short peptides from the 'a-region' of protein kinases which selectively modulate protein kinase activity
ZA975380B (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors.
WO1999043830A3 (en) Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2005040073A3 (en) Solid phase synthesis of 3-aryl-2- indolylcarboxylic acids
WO1996040113A3 (en) Phosphatase inhibitors
WO1997008190A3 (en) Compounds
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 213-234, DESCRIPTION, REPLACED BY NEW PAGES 213-234; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2325935

Country of ref document: CA

Ref document number: 2325935

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 537851

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999915018

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999915018

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999915018

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)